Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and an immunotherapy for oncology and other indications. Its development programs include CBLB612, which is in preclinical studies, a synthetic molecule that activates the toll-like heterodimeric receptor 2/6 and stimulated white blood cell generation; and that has completed Phase II for treating myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy. The company is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CBLI
Previous Symbol
CUSIPN/A
Phone716-849-6810
Debt
Debt-to-Equity RatioN/A
Current Ratio3.54
Quick Ratio3.54
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.95 million
Price / Sales9.91
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.66 per share
Price / Book2.59
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-9,700,000.00
Net Margins-245.29%
Return on Equity-75.80%
Return on Assets-56.63%
Miscellaneous
Employees19
Outstanding Shares11,300,000
Market Cap$19.32 million
OptionableNot Optionable
Cleveland BioLabs (NASDAQ:CBLI) Frequently Asked Questions
What is Cleveland BioLabs' stock symbol?
Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI."
How were Cleveland BioLabs' earnings last quarter?
Cleveland BioLabs, Inc. (NASDAQ:CBLI) released its earnings results on Wednesday, November, 14th. The biotechnology company reported ($0.10) earnings per share for the quarter. The biotechnology company had revenue of $0.28 million for the quarter. Cleveland BioLabs had a negative net margin of 245.29% and a negative return on equity of 75.80%. View Cleveland BioLabs' Earnings History.
When is Cleveland BioLabs' next earnings date?
Has Cleveland BioLabs been receiving favorable news coverage?
News articles about CBLI stock have trended positive on Sunday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cleveland BioLabs earned a news impact score of 3.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an impact on the stock's share price in the immediate future.
Who are some of Cleveland BioLabs' key competitors?
Some companies that are related to Cleveland BioLabs include Senomyx (SNMX), HedgePath Pharmaceuticals (HPPI), Dyadic International (DYAI), BIOQUAL (BIOQ), Vitality Biopharma (VBIO), Bioanalytical Systems (BASI), US Stem Cell (USRM), Geovax Labs (GOVX), ALGAE TEC LTD/S (ALGXY), Protalex (PRTX), Tenax Therapeutics (TENX), Eloxx Pharmaceuticals (ELOX), Intrexon (XON), National Research (NRCIB) and National Research (NRCIA).
Who are Cleveland BioLabs' key executives?
Cleveland BioLabs' management team includes the folowing people:
- Dr. Yakov N. Kogan M.B.A., Ph.D., MBA, Chief Exec. Officer and Interim Principal Financial Officer (Age 45)
- Dr. Langdon L. Miller, Pres & Chief Medical Officer (Age 64)
- Dr. Andrei V. Gudkov, Chief Scientific Officer (Age 62)
- Dr. Ann Lenich Hards Ph.D., Exec. VP of Regulatory Affairs
- Dr. Andrei Purmal Ph.D., VP of Chemistry
How do I buy shares of Cleveland BioLabs?
Shares of CBLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cleveland BioLabs' stock price today?
One share of CBLI stock can currently be purchased for approximately $1.71.
How big of a company is Cleveland BioLabs?
Cleveland BioLabs has a market capitalization of $19.32 million and generates $1.95 million in revenue each year. Cleveland BioLabs employs 19 workers across the globe.
What is Cleveland BioLabs' official website?
How can I contact Cleveland BioLabs?
Cleveland BioLabs' mailing address is 73 HIGH STREET, BUFFALO NY, 14203. The biotechnology company can be reached via phone at 716-849-6810 or via email at [email protected]
MarketBeat Community Rating for Cleveland BioLabs (NASDAQ CBLI)
MarketBeat's community ratings are surveys of what our community members think about Cleveland BioLabs and other stocks. Vote "Outperform" if you believe CBLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
